GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...
The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results